Alex’s practice focuses on advising clients at the intersection of transformative pharmacology, cutting edge commercial strategy, and Value, Pricing, and Access (VPA) excellence.
Alex works with global and start-up pharmaceutical and biotechnology companies on pre-launch and in-line strategy development in key global pharma markets.
Recent therapeutic area experience includes small molecule and biopharma approaches to heme and solid tumor oncology, immunological / inflammatory diseases, and extensive work in vaccine preventable diseases.
Alex joined Putnam in 2013 after receiving his Ph.D. in Experimental and Molecular Medicine from Dartmouth (focused in new drug targets to treat lung cancer) subsequent to a B.S. in Bioinformatics and Molecular Biology from Rensselaer Polytechnic Institute.